medigraphic.com
ISSN 1561-3070 (Digital)

2013, Número 3

<< Anterior Siguiente >>

Rev Cub Oftal 2013; 26 (3)


Intravítrea de acetato de triamcinolona en el edema macular secundario a oclusión venosa de rama retiniana

Llanes DS, Chiang RC, Rúa MR, Toledo GY, Pérez PM

Idioma: Español
Referencias bibliográficas: 52
Paginas: 439-451
Archivo PDF: 128.31 Kb.


RESUMEN

Objetivos: evaluar los resultados del tratamiento de intravítrea de acetato de triamcinolona, en el edema macular secundario a oclusión de rama venosa retiniana.
Métodos: estudio prospectivo, intervencional, no comparativo, que incluyó a 16 pacientes con edema macular secundario a oclusión de rama venosa retiniana. El tratamiento consistió en inyección intravítrea de triamcinolona (hasta 3 dosis) y, de ponerse tercer retratamiento se realizó grid macular. La primera dosis se puso a los 3 meses de ocurrido el evento oclusivo y se les dio seguimiento por 12 meses. Se determinaron la mejor agudeza visual corregida, grosor foveal retinal y complicaciones.
Resultados: se estudiaron 11 hombres (68,75 %) y 5 mujeres (31,25 %), con promedio de 60,1 años de edad. Del total de pacientes, 8 requirieron 1 dosis (50 %), 5 necesitaron de 2 dosis (31,25 %) y a 3 hubo de aplicarle 3 dosis (18,75 %) más grid macular. La mejor agudeza visual con corrección inicial promedio fue de 0,29 (0,05-0,5) con una mejoría a 0,64 (0,05-1,0) a los 12 meses. El grosor foveal retinal inicial promedio fue de 551,38 (346-967) µm y disminuyó a 204,06 (112-449) µm, a los 12 meses. La complicación más frecuente fue la hipertensión ocular en 4 pacientes (25,0 %).
Conclusión: la inyección intravítrea de triamcinolona constituyó un tratamiento eficaz en el edema macular secundario a oclusión de rama venosa retiniana.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Scott IV. Macular Edema Associated With Retinal Vein Occlusion. Retina Today. 2010;(4):54-5.

  2. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: Evidence based systematic review. Ophthalmology. 2010;117(6):1094-1101.

  3. Chan A, Leung LS, Blumenkranz MS. Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol 2011;5:1043-9.

  4. Shak GK. Treatment of Retinal Vein Occlusion. Individualized therapy is crucial to good patient outcomes. Retina Today [revista en Internet]. 2012 [citada 2012 abril 23];(3). Disponible en: http://www.bmctoday.net/retinatoday/2012/03/article.asp?f=treatment-of -retinalvein- occlusion

  5. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The Prevalence of Retinal Vein Occlusion Pooled Data from Population Studies from the United States, Europe, Asia and Australia. Ophthalmology. 2010;117(2):313-9.

  6. Haller JA, Brown DM. Evaluating and Integrating New Evidence in the Treatment of RVO. Retina Today [revista en Internet]. 2010 [citada 2012 abril 23];(10)Sup. 1. Disponible en: http://www.bmctoday.net/retinatoday/2010/10/supplement/article.asp?f=evaluatingand -integrating-new-evidence-in-the-treatment-of-rvo

  7. Brown DM. New Directions in RVO Treatment. Retina Today [revista en Internet]. 2010 [citada 2012 abril 23];(4) Sup. 1. Disponible en: http://www.bmctoday.net/retinatoday/2010 /04/supplement/article.asp?f=newdirections- in-rvo-treatment

  8. Ho AC, Ip MS. An Evidence-based Approach for RVO: Corticosteroids, Implants and Anti- VEGF Therapies. Retina Today [revista en Internet]. 2011 [citada 2012 abril 23];(6). Disponible en: http://www.bmctoday.net/retinatoday/2011/06/supplement/article.asp?f=anevidence -based-approach-for-rvocorticosteroids-implants-and-anti-vegf-therapies

  9. Schutze C, Schmidt-Erfurt U. Imaging for BRVO and CRVO. Retina Today [revista en Internet]. 2011 [citada 2012 abril 23];(6). Disponible en: http://www.bmctoday.net/retinatoday/2011/06/article.asp?f=imaging-for-brvo-andcrvo

  10. Rehak J, Rehak M. Branch retinal vein occlusion: Pathogenesis, visual prognosis and treatment modalities. Current Eye Research Feb 2008,33(2):111-31.

  11. Hariprasad SM. Combination Therapy for RVO. Retina Today [revista en Internet]. 2010 [citada 2012 abril 23];(5-6). Disponible en: http://www.bmctoday.net/retinatoday/2010/06 /article.asp?f=combination-therapyfor- rvo

  12. Boyer DS. The Pathophysiology of Macular Edema. Retina Today [revista en Internet]. 2011 [citada 2012 abril 23];(9) Sup. 1. Disponible en: http://www.bmctoday.net/retinatoday /2011/09/supplement/article.asp?f=thepathophysiology- of-macular-edema

  13. Noma H, Funatsu H, Mimura T, Tatsugawa M, Shimada K, Eguchi S. Vitreous inflammatory factors and serous macular Detachment in Branch Retinal Vein Occlusion. Retina. 2012;32(1):86-91.

  14. Cousins SW, Boyer DS. New and Emerging Treatment Paradigms for Macular Edema in Retinal Vein Occlusions and Diabetic Retinopathy. Retina Today [revista en Internet]. 2010 [citada 2012 abril 23];10. Disponible en: http://www.bmctoday.net/retinatoday/2010/10 /supplement/article.asp?f=evaluating-and-integrating-new-evidence-in-thetreatment- of-rvo

  15. Holekamp NM, Ip MS. Point Counteroint Early vs Late Pharmaologic Therapy for RVO. Retina Today [revista en Internet]. 2010 [citada 2012 abril 23];(8):. http://www.bmctoday.net/retinatoday/2010/08/article.asp?f=pointcounterpointearly- vs-late-pharmacologic-therapy-for -rvo

  16. Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained- release dexamethasone implant for treatment of macular edema. Clin Ophthalmol. 2011;5:139-46.

  17. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6. Arch Ophthalmol. 2009; 127(9):1115-1128.

  18. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham- controlled trial of Dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-46.

  19. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion, twelve- month study results. Ophthalmology, 2011;118(12):2453-60.

  20. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following Branch retinal vein occlusion: six month primary end point results of a phase III study. Ophthalmology 2010;117(6):1102-12.

  21. Brown DM. Clinical Implications of the BRAVO and CRUISE Trials. Retina Today. 2010;(4):38-40.

  22. Kitchens J. Baseline predictors of the number of Ranibizumab retreatment injections in the BRAVO study during months 6-11. Poster presented at: American Academy of Ophthalmology Annual Meeting; October 16-19, 2010; Chicago.

  23. Cekic O, Chang S, Tseng J, Barile G, Weissman H, Del Priore L, et al. Intravitreal Triamcinolone injection for treatment of macular edema secondary of branch retinal vein occlusions. Retina. 2005;25(7):851-5.

  24. Lee H, Shah G. Intravitreal triamcinolone as primary treatment of cystoids macular edema secondary to branch retinal vein occlusion. Retina. 2005;25(5):551-555.

  25. Ozdek S, Dern YT, Gurelik G, Hasanreisoglu B. Posterior subtenon triamcinolona, intravitreal triamcinolona and grid laser photocoagulation or the treatment of macular edema in branch retinal vein occlusion. Ophthalmic Res. 2008;40(1):26-31.

  26. Jonas JB, Kayan AK, Kamppeter B. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye. 2005;19(1):65-71.

  27. Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of Triamcinolone for Macular edema associated with Branch Retinal Vein Occlusion. Am J Ophthalmol. 2005;139(6):972-82.

  28. Yepremyan M. Early treatment of cystoids macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolona acetónida. Ophthalmic Surg Lasers Imaging. 2005;36(1):30-6.

  29. Chen S, Sudarom V, LochheddJ, Patel C. Intravitreal triamcinolona for treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2006;141(5):876-83.

  30. Cakir M, Dogan M, Bayraktar Z, Bayraktar S, Acar N, Altan T, et al. Efficacy of intravitreal triamcinolona for the treatment of macular edema secondary to branch retinal vein occlusion in eye with or without grid laser photocoagulation. Retina. 2008;28(3):465-72.

  31. Battaglia P, Iacono P, Ravalico G. Intravitreal triamcinolone acetonide combined with subthresshold grid laser treatment for macular edema in branch retinal vein occlusion: a pilot study. Br J Ophthalmol. 2008;92(8):1046-50.

  32. Jonas JB. Intravitreal injection of Triamcinolone acetónida. Essential in ophthalmology. Medical Retina. 2007;(9):142-65.

  33. Cheng KC. Intravitreal triamcinolone acetonide vs Bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye. 2009;23(11):2023-33.

  34. Kim JY, Park SP. Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein Occlusion. Korean J Ophthalmol. 2009;23(4):259-65.

  35. Saleh M Gaucher D, Letsch J, Bourcier T, Speeg-Schatz C. Efficacy of Early Injection of intravitreal triamcinolone acetonide (IV TA) versus delayed Injection for macular edema resulting from retinal vein occlusion. J Fr Ophthalmol. 2011;34(6):355-61.

  36. Shukla D, Behera UC, Chakraborty S, Mahalakshmi R, Prasad NM. Serous Macular Detachment as a Predictor of Resolution of Macular Edema with Intravitreal Triamcinolone. Ophthalmic Surg Lasers Imaging. 2009;40(2):115-9.

  37. Benson W B. A Randomized Trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. Evidence-Based Ophthalmology. 2010;11(1):22-3.

  38. Blumenkranz M, Whitcup SM. Implant a First for ME after RVO. Benefits possible from Drug Delivery, effect on inflammation. Ophthalmology Times. 2009;34(14):50-4.

  39. Morse LS, Modjjtahedi S. Use of Intravitreal Steroids in the Clinic. Retina Today [revista en Internet]. 2010 [citada 2012 abril 23];(6) Sup. 1. Disponible en: http://www.bmctoday.net/retinatoday/2010/06/supplement/article.asp?f=use-ofintravitreal- steroids-in-the-clinic

  40. Oakley RH, Cidlowski JA. Evolving Science: The Pharmacology of Steroids. Retina Today [revista en Internet]. 2010 [citada 2012 abril 23];(5) Sup. 1. Disponible en: http://www.bmctoday.net/retinatoday/2010/06/supplement/

  41. W L, Evans T. Brach Retinal Vein Occlusion: Treatment and Medication. MEDSCAPE Articles; Feb 19, 2010.

  42. Yasushi S et al. Early change of central macular Thickness after intravitreous triamcinolone or bevacizumab in Diabetic macular edema or retinal vein occlusion. Retina. 2011;31(2): 290-7.

  43. Karacorlu M, Ozdemir H Karacorlu S, Alacali N. Regression of optic nerve head neovascularization in proliferative diabetic retinopathy after intravitreal triamcinolona. Int Ophthalmol. 2004;25(2):113-116.

  44. 37Jaulim A, Badia A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: Epidemiology, Pathogenesis, Risk Factors, Clinical Features, Diagnosis and Complications. An Update of the Literature. Retina. 2013;13(5):901-10.

  45. Bertelsen M, Linneberg A, Rosenberg T, Christoffersen N, Vorum H, Gade E, et al. Comorbidity in patients with Branch retinal vein Occlusion: case-control Study. BMJ. 2012; 345:e7885.

  46. Cekic O, Cakir M. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res. 2010;35(10):925-9.

  47. Cekiç O, Chang S, Tseng JJ, Barile GR, Del Priore LV, Weissman H, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2005;25(7):8515.

  48. Krepler K, Ergun E, Sacu S, Richter-Müksch S, Wagner J, Stur M, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand. 2005; 83(5):600-4.

  49. Chen CH, Chen YH,Wu PC, Chen YJ, Lee JJ, Liu YC, et al. Treatment of branch retinal vein occlusion induced macular edema in treatment-naïve cases with a single intravitreal triamcinolone or bevacizumab injection. Chang Gung Med J.2010 Jul- Aug;33(4):424-35.

  50. Guthoff R, Meigen T, Hennemann K, Schrader W. Comparison of Bevacizumab and triamcinolone for treatment of macular edema secondary to branch retinal vein occlusion in a pair-matched analysis. Ophthalmologica. 2010;224(5):319-24.

  51. Chuang LH, Yeung L. Secondary ocular hypertension after intravitreal injection with 2mg or 4 mg of triamcinolone in retinal vein occlusion. J Ocul Pharmacol Ther. 2010;26(4):325-8.

  52. Gallemare RP, Wallsh J. Management of Retinal Vein Occlusion: What the Clinical Trials Tell Us. Retina Today [revista en Internet]. 2013 [citada 2013 may 05];(4). Disponible en: http://www.bmctoday.net/retinatoday /2013/04/article.asp?f=management-of-retinal-vein-occlusion-what-the-clinical-trialstell- us




2020     |     www.medigraphic.com